Login
$DNA
$8.50 +$0.00 (0.0%) After hours

$DNA 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

Ginkgo provides an update on its third quarter financial results and the growth of its two prevailing offerings built on one autonomous lab platform: Autonomous Labs and Cloud Lab

29 Oct 2026 8-K: Regulation FD Disclosure

Presentation and Q&A session scheduled for post-market on Thursday, November 5, 2026

05 Aug 2026 8-K: Results of Operations and Financial Condition

Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of Maryland

30 Jul 2026 8-K: Regulation FD Disclosure

Presentation and Q&A session scheduled for post-market on Wednesday, August 5, 2026

12 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 11, 2026, Ginkgo Bioworks Holdings, Inc. (the “Company”) held its 2026 annual meeting of shareholders (the “Annual Meeting”). A total of 39,536,848 shares of Class A common stock and 8,405,525 shares of Class B common stock were ...

07 May 2026 8-K: Results of Operations and Financial Condition

Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab

07 Apr 2026 8-K: Completion of Acquisition or Disposition of Assets

On April 3, 2026, Ginkgo Bioworks, Inc. (the “Seller”), a wholly owned subsidiary of Ginkgo Bioworks Holdings, Inc. (the “Company”), completed a transaction with Tower Biosecurity, Inc. also known as Perimeter Systems, Inc. (the “Purchas...

27 Feb 2026 8-K: Entry into a Material Definitive Agreement

Section 6.06 Return of Assets; Transfer of Business Assets 46

26 Feb 2026 8-K: Results of Operations and Financial Condition

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business

23 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

On December 18, 2025, Ginkgo Bioworks Holdings, Inc. (the “Company”) announced that Dr. Reshma Shetty, the Company’s President, Chief Operating Officer, and member of the Board of Directors, will transition her Chief Operating Officer du...

06 Nov 2025 8-K: Results of Operations and Financial Condition

Ginkgo provides an update on its third quarter financial results

04 Sep 2025 8-K: Entry into a Material Definitive Agreement

Ginkgo Bioworks Holdings, Inc.Shares of Class A Common Stock

29 Aug 2025 8-K: Other Events

On May 27, 2025, Ginkgo Bioworks Holdings, Inc. (the “Company”) entered into a Stipulation and Agreement of Settlement (the “Stipulation of Settlement”) to resolve certain stockholder derivative actions commenced nominally on behalf of t...

07 Aug 2025 8-K: Results of Operations and Financial Condition

Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets

13 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 12, 2025, Ginkgo Bioworks Holdings, Inc. (the “Company”) held its 2025 annual meeting of shareholders (the “Annual Meeting”). A total of 34,795,259 shares of Class A common stock and 8,371,744 shares of Class B common stock were ...

21 May 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

BOSTON, Mass. May 21, 2025 – Ginkgo Bioworks (NYSE: DNA, “Ginkgo” or the “Company”), which is building the leading platform for cell programming and biosecurity, today announced that Mark Dmytruk, the Company’s Chief Financial Officer, i...

06 May 2025 8-K: Results of Operations and Financial Condition

Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target

25 Feb 2025 8-K: Results of Operations and Financial Condition

Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an expanded cost savings target

12 Nov 2024 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions

04 Sep 2024 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Other Events

On September 3, 2024, the New York Stock Exchange (the “NYSE”) notified Ginkgo Bioworks Holdings, Inc. (the “Company”), and, on September 4, 2024, publicly announced, that the NYSE has determined to (a) commence proceedings to delist the...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support